Glycemic Control Over Multiple Decades and Dementia Risk in People With Type 2 Diabetes
- PMID: 37067815
- PMCID: PMC10111232
- DOI: 10.1001/jamaneurol.2023.0697
Glycemic Control Over Multiple Decades and Dementia Risk in People With Type 2 Diabetes
Abstract
Importance: The levels of glycemic control associated with the lowest risk of dementia in people with type 2 diabetes are unknown. This knowledge is critical to inform patient-centered glycemic target setting.
Objective: To examine the associations between cumulative exposure to various ranges of glycated hemoglobin (HbA1c) concentrations with dementia risk across sex and racial and ethnic groups and the association of current therapeutic glycemic targets with dementia risk.
Design, setting, and participants: This cohort study included members of the Kaiser Permanente Northern California integrated health care system with type 2 diabetes who were aged 50 years or older during the study period from January 1, 1996, to September 30, 2015. Individuals with fewer than 2 HbA1c measurements during the study period, prevalent dementia at baseline, or less than 3 years of follow-up were excluded. Data were analyzed from February 2020 to January 2023.
Exposures: Time-updated cumulative exposure to HbA1c thresholds. At each HbA1c measurement, participants were categorized based on the percentage of their HbA1c measurements that fell into the following categories: less than 6%, 6% to less than 7%, 7% to less than 8%, 8% to less than 9%, 9% to less than 10%, and 10% or more of total hemoglobin (to convert percentage of total hemoglobin to proportion of total hemoglobin, multiply by 0.01).
Main outcomes and measures: Dementia diagnosis was identified using International Classification of Diseases, Ninth Revision codes from inpatient and outpatient encounters. Cox proportional hazards regression models estimated the association of time-varying cumulative glycemic exposure with dementia, adjusting for age, race and ethnicity, baseline health conditions, and number of HbA1c measurements.
Results: A total of 253 211 participants were included. The mean (SD) age of participants was 61.5 (9.4) years, and 53.1% were men. The mean (SD) duration of follow-up was 5.9 (4.5) years. Participants with more than 50% of HbA1c measurements at 9% to less than 10% or 10% or more had greater risk of dementia compared with those who had 50% or less of measurements in those categories (HbA1c 9% to <10%: adjusted hazard ratio [aHR], 1.31 [95% CI, 1.15-1.51]; HbA1c≥10%: aHR, 1.74 [95% CI, 1.62-1.86]). By contrast, participants with more than 50% of HbA1c concentrations less than 6%, 6% to less than 7%, or 7% to less than 8% had lower risk of dementia (HbA1c<6%: aHR, 0.92 [95% CI, 0.88-0.97]; HbA1c 6% to <7%: aHR, 0.79 [95% CI, 0.77-0.81]; HbA1c 7% to <8%: aHR, 0.93 [95% CI, 0.89-0.97]).
Conclusions and relevance: In this study dementia risk was greatest among adults with cumulative HbA1c concentrations of 9% or more. These results support currently recommended relaxed glycemic targets for older people with type 2 diabetes.
Conflict of interest statement
Figures
Similar articles
-
Glycated Hemoglobin A1c Time in Range and Dementia in Older Adults With Diabetes.JAMA Netw Open. 2024 Aug 1;7(8):e2425354. doi: 10.1001/jamanetworkopen.2024.25354. JAMA Netw Open. 2024. PMID: 39093563 Free PMC article.
-
Risk of Dementia Among Patients With Diabetes in a Multidisciplinary, Primary Care Management Program.JAMA Netw Open. 2024 Feb 5;7(2):e2355733. doi: 10.1001/jamanetworkopen.2023.55733. JAMA Netw Open. 2024. PMID: 38345817 Free PMC article.
-
Long-term Glycemic Control and Dementia Risk in Type 1 Diabetes.Diabetes Care. 2018 Nov;41(11):2339-2345. doi: 10.2337/dc18-0073. Epub 2018 Sep 4. Diabetes Care. 2018. PMID: 30181165 Free PMC article.
-
Cause-specific risk of major adverse cardiovascular outcomes and hypoglycemic in patients with type 2 diabetes: a multicenter prospective cohort study.Endocrine. 2019 Jan;63(1):44-51. doi: 10.1007/s12020-018-1715-0. Epub 2018 Aug 18. Endocrine. 2019. PMID: 30121774 Clinical Trial.
-
Association between Glycosylated Hemoglobin Levels and Vaccine Preventable Diseases: A Systematic Review.Diseases. 2024 Aug 17;12(8):187. doi: 10.3390/diseases12080187. Diseases. 2024. PMID: 39195186 Free PMC article. Review.
Cited by
-
Systemic determinants of brain health in ageing.Nat Rev Neurol. 2024 Nov;20(11):647-659. doi: 10.1038/s41582-024-01016-z. Epub 2024 Oct 7. Nat Rev Neurol. 2024. PMID: 39375564 Review.
-
Management of older adults with diabetes mellitus: Perspective from geriatric medicine.J Diabetes Investig. 2024 Oct;15(10):1347-1354. doi: 10.1111/jdi.14283. Epub 2024 Aug 8. J Diabetes Investig. 2024. PMID: 39115890 Free PMC article. Review.
-
Glycated Hemoglobin A1c Time in Range and Dementia in Older Adults With Diabetes.JAMA Netw Open. 2024 Aug 1;7(8):e2425354. doi: 10.1001/jamanetworkopen.2024.25354. JAMA Netw Open. 2024. PMID: 39093563 Free PMC article.
-
HbA1c variability associated with dementia risk in people with type 2 diabetes.Alzheimers Dement. 2024 Aug;20(8):5561-5569. doi: 10.1002/alz.14066. Epub 2024 Jul 3. Alzheimers Dement. 2024. PMID: 38959429 Free PMC article.
-
Glycemic Control, Cognitive Aging, and Impairment Among Diverse Hispanic/Latino Individuals: Study of Latinos- Investigation of Neurocognitive Aging (Hispanic Community Health Study/Study of Latinos).Diabetes Care. 2024 Jul 1;47(7):1152-1161. doi: 10.2337/dc23-2003. Diabetes Care. 2024. PMID: 38684486 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
